Form 4: Matthew Strobeck Reports Changes in Beneficial Ownership of Biodesix Inc. (BDSX) Stock Following Conversion of Preferred Stock

Director Matthew Strobeck reports changes in beneficial ownership of Biodesix Inc. stock due to the conversion of Series A Non-Voting Convertible Preferred Stock into common stock, along with the grant of restricted stock units and stock options.

Summary

• On May 23, 2024, Matthew Strobeck reported changes in his beneficial ownership of Biodesix Inc. (BDSX) stock.
• The changes are primarily due to the conversion of Series A Non-Voting Convertible Preferred Stock into common stock, which was approved by stockholders on May 21, 2024.
• Strobeck also acquired 53,726 restricted stock units (RSUs) and 37,050 stock options on May 21, 2024.
• The RSUs vest on March 31, 2025, subject to continued service, and represent a contingent right to receive one share of common stock each.
• The stock options, with an exercise price of $1.57, also vest on March 31, 2025, subject to continued service, and expire on May 20, 2034.
• Strobeck holds shares directly and indirectly through Birchview Fund LLC, Birchview Capital Separately Managed Account, UTMA Accounts, and Clajer Capital LLC.
• He disclaims beneficial ownership of shares held by these entities except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing detailing changes in stock ownership. It doesn't contain overtly positive or negative information, hence a neutral sentiment score.

Positives

• The conversion of preferred stock to common stock simplifies the capital structure of Biodesix Inc.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The conversion of preferred stock to common stock may impact shareholders by diluting the ownership percentage of existing common stockholders.

Key Dates